Medical Benefit Drug Prior Authorizations: What Specialty Practices Should Be Preparing for Next

Prior authorization has long been one of the most resource-intensive administrative challenges in specialty care, particularly for therapies billed under the medical benefit.

For infusion centers and specialty practices managing biologics, authorization workflows often involve far more than submitting a request and waiting for approval. Coverage criteria, clinical documentation requirements, payer-specific policies, benefits verification, and treatment timing all play a role in determining whether therapy moves forward without delays.

That complexity may increase as CMS and commercial payers continue moving toward more coordinated, technology-enabled authorization workflows.

CMS has proposed changes to advance electronic prior authorization for medical-benefit drugs, signaling continued progress toward more standardized, digital authorization workflows across healthcare. While implementation timelines and payer adoption will vary, the broader direction is becoming clear. Prior authorization processes are becoming more structured, more data-driven, and more dependent on clean documentation from the start.

For specialty practices, the operational implications are significant. Strong authorization performance will increasingly depend on payer readiness long before treatment is scheduled.

What to Know

• Prior authorization requirements for medical-benefit drugs continue to become increasingly rigorous and documentation-driven.
• CMS’ push toward electronic prior authorization signals broader workflow changes across payer environments.
• Infusion and biologic therapy programs may face increased pressure to improve documentation accuracy, benefits verification, and submission readiness.
• Front-end workflow performance increasingly influences treatment timelines, reimbursement, and operational efficiency.

The Operational Demands of Medical Benefit Authorizations

Medical-benefit drugs create a unique reimbursement environment compared with many traditional pharmacy-benefit medications. Therapies billed under the medical benefit often require coordination across clinical, administrative, and revenue cycle teams before treatment can begin. This is especially true for infused biologics, physician-administered therapies, and specialty medications used in rheumatology, gastroenterology, neurology, and immunology.

Authorization approval often depends on multiple factors, including diagnosis validation, step therapy requirements, prior treatment history, site-of-care restrictions, and payer-specific clinical criteria.

Missing clinical notes, incomplete treatment history, coding inconsistencies, or outdated insurance information can trigger denials, requests for additional information, or authorization resubmissions. For high-cost biologic therapies, those delays can disrupt scheduling, medication coordination, staffing efficiency, reimbursement timelines, and continuity of patient care.

CMS Signals a Shift Toward More Digital Authorization Workflows

CMS’ proposed rule around prior authorization and interoperability reflects a broader industry shift toward electronic workflow standardization.

The goal is to improve transparency, reduce administrative burden, and support faster authorization decisions through better data exchange between providers, payers, and health IT systems.

For specialty practices, the significance goes beyond technology. Electronic prior authorization may improve efficiency over time, but it also creates greater visibility into workflow quality. When authorization systems are standardized, errors and omissions become easier to identify and harder to work around.

In practical terms, payer expectations for clean, complete, and timely submissions may continue to rise as authorization workflows become more rigorous, exposing operational inefficiencies more quickly.

Questions Worth Asking Your Provider

When you do connect with your healthcare team, these conversations can be productive:

• Is my current treatment plan still the right fit for where my asthma is now?
• Could allergies be contributing to what I’m experiencing?
• How should I monitor local air quality and pollen levels?
• What should my plan be during extreme heat or wildfire smoke events?
• Are there additional treatment options I should know about, including biologics for severe asthma?

For some people whose asthma remains difficult to control despite standard therapies, biologic medications may be an option worth exploring. These treatments work by targeting specific pathways involved in asthma-related inflammation and may help reduce the frequency and severity of exacerbations in appropriate candidates. Your provider can help determine whether this kind of therapy is relevant to your situation.

You don’t need to skip summer activities because of your asthma. With the right information and an open conversation with your healthcare team, it’s possible to stay active and feel more confident throughout the season.

Where Specialty Practices Should Focus Now

The most effective preparation often starts with stronger front-end workflow performance. As prior authorization requirements become more standardized, specialty practices may benefit from assessing whether their authorization workflows consistently support clean, complete, and timely submissions.

Benefits verification remains a critical first step. Coverage changes, policy updates, and site-of-care requirements can shift quickly, particularly for specialty medications. Verifying benefits early helps reduce downstream surprises and allows teams to identify potential barriers before treatment scheduling begins.

Documentation quality plays an equally important role. Clinical records should clearly support medical necessity and align with payer criteria. This includes diagnostic details, relevant labs, prior treatment history, step therapy documentation, and supporting physician notes when required.

Workflow coordination across departments is another major factor. Authorization performance often depends on how effectively intake, clinical, scheduling, pharmacy, and billing teams communicate. Even when clinical eligibility is clear, breakdowns between teams can create unnecessary delays.

High-performing specialty practices increasingly view authorization as an operational workflow rather than simply an administrative task. That shift can help reduce delays while supporting stronger treatment continuity, reimbursement performance, and overall workflow efficiency.

Frequently Asked Questions

When could CMS electronic prior authorization requirements for medical-benefit drugs take effect?

CMS has proposed October 1, 2027, as the implementation date for impacted payers to support electronic prior authorization for drugs covered under the medical benefit, pending final rulemaking.

While timelines may change, the proposal signals continued movement toward more data-driven and interoperable authorization workflows.

Specialty practices may benefit from strengthening documentation, benefits verification, and payer-readiness workflows now rather than waiting for formal implementation.

How could electronic prior authorization affect specialty practices?

Electronic prior authorization may improve workflow efficiency over time, but it may also increase pressure for cleaner documentation and stronger front-end processes. Practices with inconsistent workflows may experience more delays or administrative friction.

Which workflows matter most for authorization success?

Authorization performance is often shaped by front-end workflow quality. Benefits verification, documentation accuracy, coding validation, payer policy review, and strong cross-team communication all play critical roles in reducing preventable delays and supporting cleaner submissions.

How can specialty practices improve prior authorization approval rates?

Improving prior authorization approval rates often starts with reducing preventable workflow gaps before submission. Stronger benefits verification, complete clinical documentation, accurate coding, and better alignment with payer requirements can help practices submit cleaner authorization requests and reduce avoidable delays, denials, or resubmissions.